The Use of PET in the Evaluation of Tumors in Children with Neurofibromatosis Type 1

Fisher, Michael J.

doi:10.1016/j.cpet.2009.04.005

Cited by 4 publications

(1 citation statement)

References 161 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the addition of 11C methionine to PET/CT improved its specificity in equivocal NF1 cases ( 26 ). Among these, a study suggested amino acid preparations with half-lives and novel tracers for measuring DNA or cell membrane synthesis should also be considered ( 27 ).…”

Section: Resultsmentioning

confidence: 99%

Image-Based Differentiation of Benign and Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

Huang

Wang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Neurofibromatosis type 1 (NF1) is a dominant hereditary disease characterized by the mutation of the NF1 gene, affecting 1/3000 individuals worldwide. Most NF1 patients are predisposed to benign peripheral nerve sheath tumors (PNSTs), including cutaneous neurofibromas (CNFs) and plexiform neurofibromas (PNFs). However, 5%-10% of PNFs will ultimately develop into malignant peripheral nerve sheath tumors (MPNSTs), which have a poor prognosis. Early and reliable differentiation of benign and malignant tumors in NF1 patients is of great necessity. Pathological evaluation is the “gold standard” for a definite diagnosis, but the invasive nature of the biopsy procedure restricts it from applying as a screening tool during the decades-long follow-up of these patients. Non-invasive image-based diagnostic methods such as CT and MRI are often considered essential screening tools for multiple types of tumors. For NF1 patients’ lifelong regular follow-ups, these radiological methods are currently used for tumor evaluation. However, no consensus was established on screening the malignant transformation of benign PNSTs. Moreover, novel technologies like radiogenomics and PET-MRI have not been well evaluated and fully adopted for NF1 patients. This review summarizes current studies of different imaging methods for differentiating benign and malignant tumors in NF1. Meanwhile, we discussed the prospects of the usage of new tools such as radiogenomics and PET-MRI to distinguish MPNST from benign PNSTs more precisely. Summarizing these findings will help clarify the directions of future studies in this area and ultimately contribute to the radiology images-based clinical screening of MPNST in NF1 patients and finally improve the overall survival rates of these patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Image-Based Differentiation of Benign and Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

Huang

Wang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Diverse Behavior in 18F-Fluorocholine PET/CT of Brain Tumors in Patients With Neurofibromatosis Type 1

Pardo

Moreno²,

Aragón³

et al. 2019

Clin Nucl Med

View full text Add to dashboard Cite

Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder that causes CNS tumors in around 20% of patients, being pilocytic astrocytomas (PA), and particularly optic pathway gliomas (OPG), the most common. We present three cases of NF1 patients referred for 18F-fluorocholine PET/CT because of suspected glioma in the setting of ongoing FUMEGA (Functional and Metabolic Glioma Analysis) trial. One case turned out to be a WHO grade I ganglioglioma; the second was a high grade glioma; and the last one (negative in PET) a probable low-grade glioma.

show abstract

Optic Pathway Gliomas

Avery

Fisher²,

Liu³

2011

Journal of Neuro-Ophthalmology

146

115

View full text Add to dashboard Cite

show abstract

The Use of PET in the Evaluation of Tumors in Children with Neurofibromatosis Type 1

Cited by 4 publications

References 161 publications

Image-Based Differentiation of Benign and Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

Image-Based Differentiation of Benign and Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

Diverse Behavior in 18F-Fluorocholine PET/CT of Brain Tumors in Patients With Neurofibromatosis Type 1

Optic Pathway Gliomas

Contact Info

Product

Resources

About